RTX 021
Alternative Names: RAY-002; RTX-021Latest Information Update: 03 Nov 2022
At a glance
- Originator Ray Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Dry macular degeneration
Most Recent Events
- 19 Sep 2022 Early research in Dry macular degeneration in USA (Parenteral) (Ray therapeutics website, September 2022)